Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Fludarabine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 6/20 | 0.82 |
| ▸ | P2RY1 | P47900 | 8/20 | 0.73 |
| ▸ | P2RY11 | Q96G91 | 5/20 | 0.73 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.73 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.73 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL3511 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL1650192 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL13046080 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL17541855 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL482449 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL23884975 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL899922 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL8401646 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL21173132 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL30350656 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024152052-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | AREVA PHARMACEUTICALS INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-9828409-B2 | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides | ZHONG MINGHONG (US) | 2017-11-28 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | ZHONG MINGHONG (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | ZHONG MINGHONG (US) | 2015-09-24 | — | — | US | disclosed |
| US-20140227277-A1 | Combination therapy with an anti-CD19 antibody and a purine analog | MORPHOSYS AG (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | IHI CORPORATION (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20070060745-A1 | Process for the preparation of fludarabine phosphate | ADORKEM TECHNOLOGY SPA (IT) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | SSBP1, KCNN1, IMMT | CA5A 919/4885NT5E 4253/4885P2RY1 4133/4885 |
| US-20070060745-A1 | Process for the preparation of fludarabine phosphate | TYMP, DCTD, PNP | CA5A 1852/4885NT5E 78/4885P2RY1 490/4885 |
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | TYMP, ENPP3, PNP | CA5A 3793/4885NT5E 547/4885P2RY1 149/4885 |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | CA5A 4755/4885NT5E 3283/4885P2RY1 2743/4885 |
| US-20140227277-A1 | Combination therapy with an anti-CD19 antibody and a purine analog | BCL6B, BCL6, CD22 | CA5A 2539/4885NT5E 92/4885P2RY1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.